Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

J&J (JNJ) to buy back $5 billion worth of shares. It also reaffirms its financial guidance for 2022.

J&J (JNJ) Announces $5B Stock Repurchase Program, Stock Up

APA Corporation

Until the Inflation Reduction Act that was enacted last month, corporate stock repurchase announcements had fallen off a cliff in 2022.

More Buybacks on the Way, but Are Dividends Better for Shareholders?

Chevron

Diageo

Coca-Cola

Kroger

Mondelez

Procter & Gamble

The stock market bounced back some on Wednesday, after the worst day since June of 2020, when the COVID-19 pandemic was in full effect.

7 ‘Strong Buy' Warren Buffett Dividend Stocks May Be Safe Havens If the Market Crashes

Investors cheered the pharmaceutical giant's latest move.

Why Johnson & Johnson Was Such a Healthy Stock Today

Johnson & Johnson (NYSE:JNJ ) Morgan Stanley 20th Annual Global Healthcare Conference September 14, 2022 11:10 AM ET CorporateParticipants Joaquin Duato - Chief Executive Officer Joe Wolk - Chief Financial Officer ConferenceCall Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Well, thanks for joining us, everybody.

Johnson & Johnson (JNJ) Morgan Stanley 20th Annual Global Healthcare Conference

Shares of Johnson & Johnson JNJ, -2.60% jumped 0.7% in premarket trading Wednesday, after the the pharmaceutical and consumer health products company announced a $5 billion stock repurchase program. The program, which represents 1.2% of J&J's market capitalization of $424.17 billion as of Tuesday's closing stock price, has no time limit.

Johnson & Johnson stock gains after $5 billion stock repurchase program announced

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock. “The last few years have demonstrated the resilience of Johnson & Johnson. With continued confidence in our business and pipeline, the Board of Directors and management team believe that Company shares are an attractive investment opportunity,” said Joaquin Duato, Chief Executive Officer. “With ou

Johnson & Johnson Announces $5 Billion Share Repurchase Program

Investors could heavily benefit from an increased level of defense in their portfolios amid the challenging macroeconomic backdrop we've found ourselves in.

These 3 Low-Beta Stocks Are Great Shields Against Volatility

Abbott Labs

We believe that healthcare companies Abbott stock (NYSE: ABT) and Johnson & Johnson stock (NYSE: JNJ) are likely to offer similar returns over the next three years.

Pick Either Johnson & Johnson Stock Or This Healthcare Company – Both Are Likely To Offer Similar Returns

Johnson & Johnson (NYSE:JNJ) has reached a A$300 million ($204.90 million) settlement in two Australian class action suits filed by Shine Lawyers for selling defective pelvic mesh implants to Australian women, Reuters reported. "The settlement reached on September 9, 2022 is the largest settlement in a product liability class action in Australian history, and is subject to approval by the Federal Court," Shine Lawyers said in a statement on its website.

Johnson & Johnson reaches $205M settlement in Australian pelvic mesh class action

Shine Lawyers said on Monday they welcome a A$300 million ($204.90 million) settlement in two Australian class action lawsuits against Johnson & Johnson that sought damages for Australian women receiving pelvic mesh implants.

Shine Lawyers reach settlement with J&J in Australian pelvic mesh class action

Air Products and Chemicals

Lowe's

These great dividend stocks have clear tailwinds that should drive long-term growth.

3 Dividend Aristocrats Set to Win Big From Unstoppable Trends

Start Time: 11:00 January 1, 0000 11:30 AM ET Johnson & Johnson (NYSE:JNJ ) 2022 Wells Fargo Healthcare Conference September 07, 2022, 11:00 AM ET Company Participants Ashley McEvoy - EVP, Worldwide Chairman, MedTech Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen All right. Good morning, everyone.

Johnson & Johnson (JNJ) Management Presents at 2022 Wells Fargo Healthcare Conference (Transcript)

Boeing

Disney

Goldman Sachs

McDonald's

Here are five Dow Jones Industrial Average stocks to check out right now.

5 Dow Jones Industrial Average Stocks To Watch In September 2022

Amgen

American Express

Caterpillar

Walmart

Today I'm writing about Dow stocks to buy. Seasoned investors are realizing that many of the 30 members of the Dow Jones Industrial Average (DJIA) are now trading at low valuation levels and prices.

7 Dow Stocks With Superior Fundamentals

Apple

Accenture Plc

Alphabet

Microsoft

Texas Instruments

UnitedHealth Group

U.S. Bancorp

Wells Fargo

Famed investor Jeremy Grantham — known for predicting several asset bubbles in the past — says the S&P 500 is in a "superbubble." The post Jeremy Grantham Bets 10 Stocks Will Protect Him From 'Superbubble' appeared first on Investor's Business Daily.

Jeremy Grantham Bets 10 Stocks Will Protect Him From 'Superbubble'

AbbVie

Gilead Sciences

One word describes these three stocks and their dividends -- solid.

3 Great Dividend Stocks to Buy in September

Colgate-Palmolive

Federal Realty Investment Trust

Genuine Parts

Hormel Foods

September is here and, apparently, so is the return of the bear market. This time, if there is not a stand by the bulls at the 3,900 level on the venerable S&P 500, then we could be on our way to test the June market lows.

Why 7 Analyst Favorite Dividend Kings Could Be Huge Bear Market Winners

Amazon

STORE Capital

Riding the Oracle of Omaha's coattails has been a moneymaking strategy for more than 50 years!

3 Warren Buffett Stocks to Buy Hand Over Fist In September

Johnson & Johnson has agreed to pay $40.5 million to settle New Hampshire's claims over the company's role in the opioid epidemic.

J&J to pay $40.5 million to settle New Hampshire opioid lawsuit

Cisco Systems

Low volatility dividend plays are built to show their worth over time. These three stocks have historically helped navigate investors through turbulent waters.

Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times

Bristol-Myers

Oil stocks were S&P 500 winners Monday, including Diamondback Energy. Bristol Myers Squibb was among the big losers.

News for Johnson & Johnson Stock (JNJ)